Laromestrocel

InterventionPhase 2

1 paper2 findings

  • 1 lab
  • Human trial1

Outcomes

2

Soluble TIE2

downin humans1

1 study
  1. Laromestrocel decreases soluble TIE2 in humans.

    “increasing doses of laromestrocel are associated with decreases in soluble (degraded) tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (TIE2)”

    Human trial

    Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty

    Cell stem cell25 Feb 2026

More on Soluble TIE2

6-minute walk distance

upin humans1

1 study
  1. Laromestrocel increases 6-minute walk distance in humans (63.4 m (95% CI: 17.1-109.6 m; p = 0.0077)).

    “Laromestrocel infusion results in clinically meaningful, dose- and time-dependent increases in the 6-min walk test (6MWT; primary endpoint) compared with placebo: 63.4 m (95% confidence interval [CI]: 17.1-109.6 m; p = 0.0077) at month 9”

    Human trial9 months

    Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty

    Cell stem cell25 Feb 2026

Development

Companies
  • LongeveronPhase 2hypoplastic left heart syndrome, aging frailty

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months